Smith & Nephew SNATS (NYSE:SNN) Rating Lowered to Hold at Wall Street Zen

Smith & Nephew SNATS (NYSE:SNN) was downgraded by investment analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued on Sunday.

Several other equities research analysts have also commented on SNN. Barclays lowered shares of Smith & Nephew SNATS from an “equal weight” rating to an “underweight” rating in a research note on Wednesday, August 5th. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Smith & Nephew SNATS in a research report on Thursday, August 6th. Weiss Ratings lowered Smith & Nephew SNATS from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday, June 11th. The Goldman Sachs Group restated a “buy” rating on shares of Smith & Nephew SNATS in a research report on Monday, May 25th. Finally, Zacks Research downgraded Smith & Nephew SNATS from a “hold” rating to a “strong sell” rating in a research note on Friday, August 7th. Two equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Smith & Nephew SNATS presently has an average rating of “Hold” and an average price target of $30.93.

Smith & Nephew SNATS Trading Down 0.4%

SNN stock opened at $29.69 on Friday. The company has a quick ratio of 1.11, a current ratio of 2.14 and a debt-to-equity ratio of 0.62. Smith & Nephew SNATS has a fifty-two week low of $28.56 and a fifty-two week high of $38.79. The firm’s 50-day simple moving average is $30.44 and its 200 day simple moving average is $31.98.

Institutional Trading of Smith & Nephew SNATS

A number of institutional investors have recently made changes to their positions in SNN. Equity Investment Corp boosted its holdings in shares of Smith & Nephew SNATS by 3.9% in the fourth quarter. Equity Investment Corp now owns 7,502 shares of the medical equipment provider’s stock valued at $246,000 after acquiring an additional 285 shares in the last quarter. Smartleaf Asset Management LLC raised its holdings in Smith & Nephew SNATS by 13.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 2,820 shares of the medical equipment provider’s stock worth $93,000 after purchasing an additional 334 shares in the last quarter. Cary Street Partners Financial LLC lifted its position in Smith & Nephew SNATS by 1.8% in the fourth quarter. Cary Street Partners Financial LLC now owns 20,255 shares of the medical equipment provider’s stock worth $665,000 after purchasing an additional 365 shares during the period. Parallel Advisors LLC lifted its position in Smith & Nephew SNATS by 20.0% in the first quarter. Parallel Advisors LLC now owns 2,322 shares of the medical equipment provider’s stock worth $74,000 after purchasing an additional 387 shares during the period. Finally, Clearstead Trust LLC bought a new position in Smith & Nephew SNATS during the 2nd quarter valued at $25,000. 25.64% of the stock is owned by institutional investors and hedge funds.

About Smith & Nephew SNATS

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.